Thornburg Investment Management Inc. Increases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Thornburg Investment Management Inc. increased its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 91.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 59,004 shares of the company's stock after buying an additional 28,124 shares during the quarter. Thornburg Investment Management Inc. owned 0.09% of Vera Therapeutics worth $2,495,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Huntington National Bank acquired a new position in shares of Vera Therapeutics in the fourth quarter valued at approximately $26,000. AlphaQuest LLC bought a new stake in Vera Therapeutics in the fourth quarter valued at approximately $34,000. KBC Group NV boosted its holdings in Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after acquiring an additional 1,387 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in Vera Therapeutics by 16.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after acquiring an additional 639 shares during the last quarter. Finally, Moors & Cabot Inc. bought a new stake in Vera Therapeutics in the fourth quarter valued at approximately $220,000. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Stock Up 0.1%

VERA traded up $0.01 during mid-day trading on Friday, reaching $19.64. 1,064,297 shares of the stock were exchanged, compared to its average volume of 782,385. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The stock has a market capitalization of $1.25 billion, a PE ratio of -7.52 and a beta of 1.28. The company has a 50 day moving average price of $22.74 and a two-hundred day moving average price of $33.10. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the company posted ($0.56) EPS. As a group, research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. JPMorgan Chase & Co. reduced their target price on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a report on Tuesday, March 4th. Wolfe Research assumed coverage on Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 target price on the stock. Guggenheim upped their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Cantor Fitzgerald reduced their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright initiated coverage on Vera Therapeutics in a report on Monday, May 5th. They issued a "buy" rating and a $75.00 target price on the stock. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $63.33.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.